GLP-1 Receptor Agonists in Diabetic Kidney Disease: from the Patient-Side to the Bench-Side.
Publication Title
American journal of physiology. Renal physiology
Document Type
Article
Publication Date
8-15-2018
Keywords
Albuminuria; Anti-inflammatory therapy; Diabetes; End-stage renal disease
Abstract
Diabetic kidney disease (DKD), one of the most common and severe microvascular complications of diabetes, is the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Since the development of renin-angiotensin system inhibition nearly three decades ago, no new therapeutic agents have received regulatory approval for treatment of DKD. Glucagon like peptide-1 (GLP-1) receptor agonists, a class of newer anti-hyperglycemic agents, have shown promise for prevention of DKD onset and progression. This perspective summarizes clinical and experimental observations to give insight into biological mechanisms beyond glycemic control, such as natriuresis and anti-inflammatory actions, for preservation of kidney function in patients with diabetes.
Clinical Institute
Kidney & Diabetes
Specialty/Research Institute
Nephrology
Specialty/Research Institute
Endocrinology
